ISLAMABAD, July 10 — For patients and families facing blood cancers, the word “remission” carries a weight that is both fragile and profound. The encouraging part about chimeric antigen receptor T-cell therapy, or CAR-T, is that early findings suggest it is offering that word to more people than ever before. The approach is deeply personal.
Doctors extract a patient’s own T-cells, those foot soldiers of the immune system, and send them to a lab. There, scientists genetically engineer the cells to express chimeric antigen receptors — a kind of homing beacon that helps the T-cells recognise and attack cancer cells.
These re-engineered cells are then infused back into the patient. It is not chemotherapy. It is not radiation.
It is, in many ways, a living drug made from the patient’s own biology. The first CAR-T therapy to reach patients was tisagenlecleucel, sold under the brand name Kymriah.
The U.S. Food and Drug Administration approved it in August 2017 for paediatric acute lymphoblastic leukaemia, a devastating diagnosis in children. Just two months later, in October 2017, the FDA approved a second therapy, axicabtagene ciloleucel, or Yescarta, for adults with large B-cell lymphoma. These were not incremental steps.
They were milestones. Clinical trials backed up the hope. The ELIANA trial, published in 2018, reported an 82 percent remission rate in paediatric patients who received Kymriah.
That figure — 82 percent — is the kind of number that changes conversations in hospital waiting rooms. It is not a guarantee, and doctors are careful to say so, but it is a real, measurable outcome in children who had often exhausted other options.
As of 2023, the FDA had approved six CAR-T therapies in total. The global market for these treatments was valued at $4.7 billion in 2022, according to a 2023 report by MarketsandMarkets, and is expected to reach $12.6 billion by 2027. That growth reflects not just commercial interest but a steady expansion of which cancers can be targeted and which patients might be eligible.
Who is behind the science
The field is driven by a small number of large pharmaceutical companies. Novartis, which developed Kymriah, remains a central player. Gilead Sciences, through its acquisition of Kite Pharma, brought Yescarta to market.
Bristol-Myers Squibb has also entered the space with its own approved therapies. These companies are not just manufacturing drugs — they are building the infrastructure for a new class of treatment that requires complex logistics, from cell extraction to genetic modification to reinfusion.
What patients should know about side effects
No treatment comes without risk, and CAR-T is no exception. The most common serious side effect is cytokine release syndrome, a systemic inflammatory response that can cause fever, low blood pressure, and difficulty breathing. Studies show it affects up to 50 percent of patients.
Neurotoxicity is another known risk, sometimes causing confusion, seizures, or difficulty speaking. Patients should talk to their doctor about these possibilities before beginning treatment.
Doctors have become better at managing these side effects since the first approvals. Hospitals that offer CAR-T therapy now have protocols in place to monitor patients closely in the days and weeks after infusion. The risks are real, but they are also increasingly understood.
The field continues to evolve. Researchers are working on next-generation CAR-T cells that might be more effective against solid tumours, which have so far proven harder to target than blood cancers.
They are also exploring ways to make the cells last longer in the body, and to reduce the risk of relapse. None of these advances are ready for patients yet, but the pipeline is active. For now, the message from oncologists is consistent: CAR-T therapy has changed the landscape for certain blood cancers.
It is not a cure for everyone. It is not a simple treatment. But for some patients, it has been transformative.
The encouraging part is that the science is still in its first decade, and the pace of discovery shows no sign of slowing. Consult your doctor for medical advice.
